You're contacting media contact of this press release

Title: Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel-Klotho Protein Therapy

United States, 14th Oct 2025 - Anzor Pharmaceuticals is pleased to announce the issuance of U.S. Patent No. 12,227,777 B2 for a novel modified soluble α-Klotho protein with enhanced therapeutic properties. This breakthrough technology represents a significant advancement in the treatment of chronic kidney disease (CKD) and conditions associated with disrupted fibroblast growth factor 23 (FGF23) signaling.Revolutionary Approach to FGF23 SignalingThe patented technology centers on a modified soluble α-Klotho protein engineered to substantially reduce binding affinity for certain FGF receptors while maintaining its critical co-receptor function for FGF23. This precision-engineered protein addresses a fundamental challenge in treating phosphate metabolism disorders and kidney disease."This patent represents years of dedicated research into understanding the complex molecular mechanisms of α-Klotho and FGF23 signaling," said Dr. Moosa Mohammadi, Chief Scientific Officer, Anzor Pharmaceuticals. "Our modified α-Klotho protein acts as an on-demand co-receptor for FGF23, offering a more targeted therapeutic approach than current treatments."Key Therapeutic ApplicationsThe modified α-Klotho protein shows promise for treating multiple conditions, including:•    Chronic Kidney Disease (CKD) and associated complications•    Hypophosphatemic conditions, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemic rickets (XLH), and tumor-induced osteomalacia (TIO)•    Renal phosphate wasting disorders•    Cardiovascular complications associated with kidney disease, including left ventricular hypertrophyScientific InnovationThe technology disclosed in the patent demonstrates seve...

This press release is issued by King Newswire